Elias Motswaledi Street Ext. West,

Brits District, North West Province

+27 12 305 4444

+27 82 843 9066


About Ketlaphela Pharmaceuticals

Ketlaphela Pharmaceuticals.

South Africa has the world’s largest ARV program, currently providing treatment to around 2.7 million people in the public health sector and over 150,000 in the private sectors (as at December 2013).

“Ketlaphela Pharmaceutical SOC Ltd ‘‘Ketlaphela’’ was created in response to the cabinet’s directive for the country to have its own State owned pharmaceutical company. Increasing local manufacturing to decrease reliance and risks associated with high level of imports for this important sector has been a priority for government that ultimately led to the call for the Ketlaphela Project.

The State owned pharmaceutical company is premised on supplying South African manufactured Active Pharmaceutical Ingredients (APIs) and final formulated medical products mainly for communicable diseases such as HIV/AIDS, Tuberculosis, and Malaria and later non-communicable diseases”. Product availability and hence security of supply will likely improve due to a closer working relationship between the Dept. of Health and a state owned company.

 The socio-economic benefits of Ketlaphela are job creation, technology transfer, reduction in the balance of Trade in pharmaceuticals through effective localization, capacity building and improving the affordability of treatments for high burden diseases, such as HIV, Tuberculosis and some non-communicable diseases.


Our vision is to be a leader in the delivery of quality and affordable medicines to the local market.


• To be the preferred supplier of local medicine
• Deliver on our promises, safely and in an
   environmentally responsible manner.
• Driving growth through Excellence, Innovation,
   Performance and Customer Focus.

Our Values

- Quality

- Integrity

- Innovation

- Reliability

- Commitment

Ketlaphela Pharmaceuticals Leadership

Mr Brian Mphahlele - Non-Executive Chairman

Mr Brian MphahleleMr Brian Mphahlele is an au fait Intellectual Property management, Commercialisation and Business Development Executive. In the period that he has been in this field, he has done negotiated & concluded a number of royalty bearing patent and know-how license deals across various industrial sectors with local and international companies (covering legal/technological/financial dimensions). He has negotiated patent pooling/collaboration agreements for joint exploitation with international organisations. He served as Chairman of the board of UViRCO Technologies (Pty) Ltd and as Non-Executive Director for NTP Radioisotopes SOC Ltd. He graduated in Science (Microbiology and Biotechnology) and Law (LLB) from Wits University and University of South Africa respectively. Mr Mphahlele also completed an accelerated executive education program presented by faculty members from University of Emory Goizueta Business School.

Mr Motheo Moatshe - Non-Executive Director
Mr Ivan M Radebe - Managing Director